72 results about "Riboside" patented technology

The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV:

The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Compositions for addressing one or more of the effects of aging are described. The compositions comprise a first component comprising repair system activator(s) such as nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid riboside (NAR), 1-methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP) and combinations thereof; a second component comprising methyl donor(s), such as S-5'-adenosyl-L-methionine (SAM), methionine, betaine, choline, folate, vitamin B12, or combinations thereof; and a third component comprising antioxidant defense activators, such as H2O2, N2S, NaSH, Na2S, and several others, including combinations thereof.Methods of administering the disclosed compositions or separate formulations of repair system activator, methyl donors, and antioxidant defense activators are also disclosed.

The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD⁺ levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.

Treatment for Cancer Using A Preparation containing a combination of one or more Natural or Synthetic or a Combination of Natural and Synthetic Boswellic Acids and one or more Natural or Synthetic or a Combination of Natural and Synthetic Cytokinins such as Kinetin, Kinetin Riboside and other Cytokinins and (the Preparation) could also contain one or more Natural or Synthetic or a Combination of Natural and Synthetic plant growth hormones such as Auxins in any percentage Ratio and could Optionally include Pharmaceutically Suitable Radioactive Agent (Radio Therapy) in any percentage ratio as a “Stand Alone” Treatment for Cancer or to Be used in Conjunction with other Pharmaceutically Suitable Therapy and Treatment(s) in any percentage ratio as a Treatment for Treating Cancer.

Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes, as it might be expected, but it induces apoptosis in B cells from patients with B-cell lymphoproliferative disorders such as B-cell chronic lymphocytic leukemia (B-CLL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), and Waldenstrom syndrome (WS). T cells are not affected. This makes acadesine and its bioprecursors (eg. its mono-, di- and tri-5′-phosphates) useful as therapeutic agents for B-cell lymphoproliferative disorders in humans. The surprising feature that T cells are virtually not affected means that the side effect (immunosuppression) is minor, what represents a therapeutical advantage of acadesine over cladribine, fludarabine and other nucleosides known in the art.

The invention relates to a freshness detecting method used for royal jelly. In the specific detecting method, the contents of adenosine triphosphate (ATP), adenosine diphosphate (ADP), single phosphoric acid adenosine (AMP), inosinic acid (IMP), hypoxanthine riboside (HxR), hypoxanthine (Hx), adenine and adenosine of the royal jelly are quantitatively determined through methods of liquid chromatography or ultraviolet spectrometry, and the like; the ratio (F value) between the accumulation amount of adenine, adenosine, HxR and Hx and the sum of the qualities of the eight substances (degradation products of ATP and nucleic acid)is calculated; the F value of the royal jelly is used for detecting the freshness of the royal jelly and judging the quality of the royal jelly. Compared with a present royal jelly quality detecting method, the freshness detecting method can judge the quality and the freshness of the royal jelly more accurately and sensitively, can improve the quality standard of the present royal jelly and effectively monitor the quality of the royal jelly.

The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD⁺ levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

The invention discloses a synthesis method of beta-nicotinamide mononucleotide, and relates to the technical field of drug synthesis. The synthesis method mainly comprises the following steps of S1, mixing and reacting nicotinamide, hexamethyldisilazane and a catalyst I in a reaction kettle to obtain silanization-protected nicotinamide; S2, adding tetraacetyl ribose, a solvent, a catalyst II and methanol for reaction so as to generate nicotinamide triacetyl riboside; S3, adding methanol and n-propylamine to generate nicotinamide riboside; S4, adding trimethyl phosphate and phosphorus oxychloride to generate beta-nicotinamide mononucleotide; and S5, separating and purifying the beta-nicotinamide mononucleoside acid. According to the invention, a plurality of continuous steps are controlledto be carried out in one reaction container, and the steps of separating and purifying an intermediate are avoided, so that the method has the advantages of high yield and high production efficiency.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

A hydrocatalyst for preparing N-(D)-deoxyriboseol-3,4-dimethylaniline as the intermediate in semi-synthesizing riboflavin is a novel alloy catalyst prepared from Raney Ni-catalyst through modifying by the transition metal elements of families I, II, IV, VI, VII and VIII chosen from Cu, Zn, Ti, Zr, Cr, Mo, Mn, Fe, Co, Ru, Rh, Pd and Pt. It contains Ni, Al and transition metal element in Wt. ratio of 1000:1000:(1-280). Its advantages are high activity, selectivity and output rate, low dosage and low cost.

The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

The present disclosure relates to a novel method, expression vectors, and host cells for producing nicotinamide riboside by regulating the pathways that lead to the production of nicotinamide riboside.

The invention provides application of hypoxanthine, hypoxanthine riboside, xanthine, xanthosine or any combination thereof in preparation of medicines for treating tumors, and belongs to the technical field of medicines. The invention further comprises application of a combination of the hypoxanthine, the hypoxanthine riboside, the xanthine, the xanthosine or any combination of the hypoxanthine, the hypoxanthine riboside, the xanthine and the xanthosine and one or more of a human basic group, nucleoside or deoxynucleoside. The hypoxanthine, the hypoxanthine riboside, the xanthine, the xanthosine or any combination thereof can be applied to chemical treatment of malignant tumors of liver cancer, lung cancer, esophagus cancer, gastric cancer, colon cancer, pancreatic cancer, prostate cancer, leukemia, promyelocytic leukemia, breast cancer, ovarian cancer, cervical cancer or T-cell lymphoma and the like, has an obvious antitumor effect, is free of myelosuppression or an important organ damage at a normal dosage, and has the antitumor effects of high efficiency, broad spectrum and low toxicity.